ARTICLE
|
doi:10.20944/preprints201805.0088.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
p53; proteasome inhibitor; endometrial cancer; ovarian cancer; gain-of-function mutation
Online: 4 May 2018 (09:03:27 CEST)